ftInvstr
MANGALAM · Healthcare ₹30.0 -1.96% Mkt Cap ₹47 Cr

MANGALAM

Healthcare Drug Manufacturers - Specialty & Generic
₹30.0
-1.96% today · 30d +10.7%
as of 2026-09-04
Price · Daily Candles
“Mangalam Dips 63.52% YoY as Net Profit Plummets 760.71%; FIIs nibble despite negative FCF.”
Mangalam faces significant headwinds, reporting a -63.52% decline in 1-year returns and a substantial -760.71% annual net profit change as of March 2026. The company is currently free-cash-flow negative, with a yield of -16.79%, impacting its valuation. Despite these challenges, FIIs increased their stake by 0.19% QoQ.
BULL CASE
+FIIs demonstrably increased their holding by 0.19% QoQ, currently owning 0.32% of the company as of March 2026.
+The stock is trading at a low Price-to-Book ratio of 0.44, significantly below its book value of ₹65.12 per share.
+The 1-month return shows a positive trend of 4.43%, suggesting some short-term recovery.
BEAR CASE
Mangalam's share price has seen a substantial decline, dropping by -63.52% over the last year and -46.67% over the past six months.
The company's annual net profit declined by a stark -760.71% as of March 2026, alongside a revenue decrease of -27.17% YoY.
Mangalam reported a negative net profit of -₹13.0 Cr for Q4 2026 and an operating profit of -₹6.0 Cr, with an OPM of -8.21%.
ML predictions for Free Cash Flow (FCF) consistently rank as 'weak' across all timeframes (e.g., FCF 1y recent 2y rank: 0.155).
Return on Capital Employed (ROCE) stands at a negative -14.0%, indicating inefficient capital utilization.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹57 Cr
-0.4% YoY
NET PROFIT
₹-8 Cr
OPM
1.77%
+9.58pp YoY
EPS
₹-4.83
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-16.4% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
With a negative ROCE of -14.0% and no reported PE, Mangalam significantly underperforms peers like Dr. Reddy's (PE 19.55, ROCE 27.63%) and Cipla (PE 29.52, ROCE 25.09%), which exhibit strong profitability and valuation metrics.
PEERPEROCE %
MANGALAM-14.0
SUNPHARMA40.4122.46
DIVISLAB69.8121.47
CIPLA29.5225.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
38
SCORE / 100
Overall
6-axis composite of the sections below.
Performance UNDERPERFORMER 5
Valuation
Growth DECLINING 17
Profitability LOW 18
Technicals STRONG 72
Risk LOW 80
Key Stats
P/B
0.44
52W HIGH
₹84.21
OFF HIGH
-64.37%
MKT CAP
₹47 Cr
◉ Active Signals
MACDBullish0.0366
RSI(14)Neutral53.47
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold MANGALAM and at what entry.

Sign up freeSign in